US Patent Issued to ALLOGENE THERAPEUTICS, PFIZER on April 21 for "DLL3 targeting chimeric antigen receptors and binding agents" (California Inventors)

ALEXANDRIA, Va., April 21 -- United States Patent no. 12,606,623, issued on April 21, was assigned to ALLOGENE THERAPEUTICS INC. (South San Francisco, Calif.) and PFIZER INC. (New York).

"DLL3 targeting chimeric antigen receptors and binding agents" was invented by Yi Zhang (Foster City, Calif.), Thomas John Van Blarcom (Oakland, Calif.), Siler Panowski (Berkeley, Calif.), Silvia K. Tacheva-Grigorova (Redwood City, Calif.) and Barbra Johnson Sasu (San Francisco).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g....